Mentholatum Issues Nationwide Recall of Rohto Eye Drops - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mentholatum Issues Nationwide Recall of Rohto Eye Drops



Mentholatum, a manufacturer of pharmaceuticals, and other healthcare products, is conducting a voluntary recall to the retail level of eye drops made in Vietnam due to a manufacturing review at the production facility in Vietnam involving sterility controls.

The recall includes only lots of Rohto Arctic, Rohto Ice, Rohto Hydra, Rohto Relief, and Rohto Cool eye drops that were manufactured in Vietnam and does not include eye drops made in Japan. Products manufactured in Japan are not included in this recall and continue to be available to consumers.

To date, there has been no evidence indicating that product does not meet specifications; however, the company is taking this action as a precautionary measure.

Source: Mentholatum

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here